Enzalutamide has joined the rapidly evolving field of ‘upfront’ therapies for metastatic prostate cancer, although Australian trial results showed mixed results when used concurrently with docetaxel. The potent androgen receptor inhibitor produced a significant improvement in overall survival when added to standard testosterone suppression therapy for patients with metastatic hormone-sensitive prostate cancer, according to interim ...
Enzalutamide the latest candidate for upfront prostate cancer therapy
By Michael Woodhead
3 Jun 2019